CoGenesys, the new spinoff from Human Genome Sciences, is expected to announce today that the FDA has OK'd its first human trials--in this case a therapy for chronic heart failure. The biotech has an unusual approach to drug development. Its executives plan to advance drug candidates through early-stage trials and then sell them to bigger pharma companies. CoGenesys will try that with Cardeva, a therapy designed to provide longer protection from a drug that currently works for only a short period.
- see the report on CoGenesys from The Washington Post